| |
|
Presenters @ AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
ABT Global at AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
AVAC at AIDS2024
|
![](../Main_/PICTURES/grey_square2.gif) |
EGPAF at AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
HPTN at AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
IntraHealth at AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
NIH at AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
PEPFAR at AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
UNITAID at AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
WHO at AIDS 2024 |
|
|
|
|
|
|
Updates @ AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
Day 2 at AIDS 2024: NIH Research Updates, Inequities, U=U, and Doxy PrEP
25th International AIDS Conference; July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Day 3 at AIDS 2024: Research Updates, HIV Criminalization Laws, and AI
25th International AIDS Conference; July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Day 4 AIDS 2024: Long-Acting Injectables, Bi-Directional Learning, PACHA & More
25th International AIDS Conference; July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Putting People First: IAS Closing Day
25th International AIDS Conference; July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
MHE Week in Review | AIDS 2024
Managed Healthcare | July 28, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Live at #AIDS2024: Highlighting U=U
HIV.gov | AIDS 2024 | July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
U=U University Conversation from AIDS 2024
25th International AIDS Conference; July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Takeaways from AIDS 2024
CSIS | August 7, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
AIDS 2024 Photo Gallery |
|
|
|
|
|
|
|
Highlights @ AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
An assessment of clinical frailty and early aging among a cohort of people living with HIV in Ontario, Canada
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Comprehensive geriatric assessment for people living with HIV and frailty: a feasibility randomized controlled trial
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Perceptions on frailty and frailty screening of people living with HIV and their healthcare professionals in Ethiopia: a qualitative study
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Frailty and multimorbidity in mid-aged and older adults living with HIV: a cross-sectional study in Zimbabwe
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Polypharmacy Contributes to Frailty & Falls - CHANGE-Rx: frailty, falls, polypharmacy, and inappropriate medication use in a Canadian cohort of...
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Hypertension management and risk of dementia in people with and without HIV infection
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United...
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Influencers and Decision-Making Factors for Choosing Injectable PrEP Among Men Who Have Sex With Men and Transgender Men in the United...
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the...
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Need for Improved HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical...
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Only 9% PrEP Use Among Transfeminine Persons: HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons...
25th International AIDS Conference | Courtesy NATAP | August 1, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
"The simplest way to go:" A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily...
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the...
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Switching from a second-line ritonavir-boosted protease inhibitor (PI/r)-based regimen to bictegravir/emtricitabine/tenofovir alafenamide...
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Extended efficacy and safety of dolutegravir and darunavir containing regimens at week 96 in the international randomised clinical trial: D2EFT
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
What drives Comorbidities in PWH Highlights From Aging Pre-Conference Talks, at AIDS 2024
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Assessing Comorbid Conditions in HIV/AIDS Patients: Insights from the CHAO (Comorbidities of HIV/AIDS Outpatients) Study in Meru County...
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Prevalence and associated factors of chronic kidney disease in young people living with HIV in Uganda
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Increased cardiovascular risk in perinatally HIV-acquired adolescents (PHIV) may linked to proinflammatory NK cells
25th International AIDS Conference | Courtesy NATAP | July 31, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
ViiV Healthcare Announces Positive New Data For Apretude Use During Pregnancy At AIDS 2024
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
ViiV Healthcare Announces Positive Data Demonstrating 2-Drug Regimen Dovato Is As Effective As 3-Drug Regimen Biktarvy For Maintenance...
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
ViiV Healthcare Premieres Early Data Showing Antiviral Activity Against Integrase Resistance From Its Investigational, Third-Generation Integrase...
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Switching to B/F/TAF in a Real-World Cohort of Older People With HIV and a High Burden of Non-AIDS-Related Comorbidities
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Fine Differences Among Five Anal Cancer Screening Strategies in HIV Group
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Preclinical Assessments of a Cabotegravir Prodrug Predicting Human Dosing Durations of >6 Months
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Prevalence of high risk penile human papillomavirus in men who have sex with men (MSM) and transgender women (TGW)
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Pre-Clinical Profiles of HIV-1 Capsid Inhibitors VH4004280 (VH-280) and VH4011499 (VH-499)
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
GS-8588, A Novel Envelope-Targeting Bispecific T-Cell Engager for HIV Cure
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Injection Site Reactions with Subcutaneous Lenacapavir Administration at Alternate Injection Sites
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Real-World Adherence of HIV-1 Oral Pre-Exposure Prophylaxis Regimens in the USA: A Group-Based Trajectory Modeling Approach
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Initial evaluation of injectable cabotegravir (CAB-LA) safety during pregnancy in the HPTN 084 open-label extension
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy
25th International AIDS Conference | Courtesy NATAP | July 30, 2024
|
|
Nonclinical Pharmacology Profile of GS-1720, a Novel, Highly Potent, Once-Weekly Oral HIV-1 Integrase Strand Transfer Inhibitor in Clinical...
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
Safety and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GS-4182, an Oral Prodrug of Lenacapavir, in Participants without HIV-1
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
Clinical Pharmacokinetics and Safety of Orally Administered VH4004280 (VH-280), a Novel HIV-1 Capsid Inhibitor, in Adults Without HIV
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
Clinical Outcomes at Month 12 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World...
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
Perspectives of People With HIV (PWH) 12 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an...
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals...
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
12-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections...
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
In vitro characterization of VH4524184 (VH-184, S-365598), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique...
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
The next Berlin patient: sustained HIV remission surpassing five years without antiretroviral therapy after heterozygous CCR5 WT/Δ32...
25th International AIDS Conference | Courtesy NATAP | July 29, 2024
|
|
|
|
Highlights @ AIDS 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
Risk of major cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: retrospective cohort analyses using routine...
25th International AIDS Conference | Courtesy NATAP | July 28, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Integrating non-communicable disease screening and treatment in antiretroviral clinics: insights from Malawi
25th International AIDS Conference | Courtesy NATAP | July 28, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
A pilot study assessing changes in cerebral function parameters in persons with insomnia switching integrase inhibitors
25th International AIDS Conference | Courtesy NATAP | July 28, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
DoxyPrEP Cuts STI Rate in FSW Without Fueling Other Infections
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
A pilot, randomized controlled trial of doxycycline pre-exposure prophylaxis versus placebo for prevention of bacterial sexually transmitted infections...
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Community-Based HCV Self-Testing Widens Testing Access in Big Vietnam Study
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Third-Generation Integrase Inhibitor Remains Active Against Resistant HIV in Lab
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral...
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Bictegravir Plus Lenacapavir Keep Control of HIV in People on Complex Regimens
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Dolutegravir-containing antiretroviral therapy and incident hypertension: findings from a prospective cohort in Kenya, Nigeria, Tanzania, and Uganda
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Additional Time PostIntegrase Inhibitor to Protease Inhibitor Switch Shows Trend to Weight Loss: DEFINE 48-week Results
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with...
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Viral suppression, viral failure and safety outcomes in children and adolescents on dolutegravir (DTG) in Europe and Thailand
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Failure to achieve undetectable viral load caused by HIV expression from defective proviruses and large reservoir size
25th International AIDS Conference | Courtesy NATAP | July 27, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Randomised placebo-controlled trial of high-dose vitamin D and low-dose calcium supplementation to improve bone density in adolescents with...
25th International AIDS Conference; July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Leaders welcome advances in HIV science while warning of growing threats to progress at 25th International AIDS Conference
25th International AIDS Conference; July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
UNAIDS urges leaders to ‘act now’ to overcome the world’s deadliest pandemic at AIDS 2024
UNAIDS | July 26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Doctor behind trial of HIV prevention drug recounts breakthrough moment
The Guardian | July 26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Experts Warn of Ongoing Monkeypox Threat Despite Progress in Vaccination and Behavioral Changes | AIDS 2024
Managed Healthcare | July 26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
Gilead | July 25, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Twice-Yearly PrEP Gives 'Huge' 100% Protection
Medscape | July 25, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
A seventh case of HIV cure reported at AIDS 2024
WHO | July 25, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
With PrEP Effort Lagging, Positive Results for Twice-Yearly Lenacapavir May Give a Lift
Managed Healthcare | July 25, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Long-Acting Injectable Cabotegravir for HIV Prevention Is Safe in Pregnancy
HIV.gov | July 25, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Research Updates, HIV Criminalization Laws, and AI (VIDEO)
NIH | July 25, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Antimicrobial resistance (AMR) in Neisseria gonorrhoeae (GC) infections among MSM on Doxycycline post-exposure prophylaxis.
25th International AIDS Conference | Courtesy NATAP | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in...
25th International AIDS Conference | Courtesy NATAP | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
No Confirmed Virological Failures (CVF) for 144 Weeks When Switching 2-/3-/4-Drug ART to DTG/3TC in Heavily Treatment-Experienced PLWHA...
25th International AIDS Conference | Courtesy NATAP | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Interventions for Improving HIV Care Continuum Outcomes Among LGBTQ+ Youth in the United States: A Narrative Review
NIH | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
HIV Science Updates from #AIDS202 with Dr. Carl Dieffenbach
HIV.gov | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Addressing Structural Barriers and HIV Criminalization
HIV.gov | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
With new HIV infections rising in a growing number of countries and regions, urgent action is needed to turn the prevention crisis around
UNAIDS | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Bridging mind and body: The interconnectedness of HIV and mental health
25th International AIDS Conference; July 22-26, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
HIV Science Updates from #AIDS202 with Dr. Carl Dieffenbach
HIV.gov | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
NIH Research Updates, Inequities, U=U, and Doxy PrEP
NIH | July 24, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
PrEPVacc HIV vaccine trial shows no reduction in infections
News Medical | July 23, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Addressing HIV Service Gaps Through Young People | AIDS 2024
Managed Healthcare | July 23, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Pediatric AIDS: Progress But Then a Plateau
Managed Healthcare | July 23, 3034
|
![](../Main_/PICTURES/grey_square2.gif) |
Ongoing Stigma Remains a Major Obstacle in the Fight Against HIV
Manager Healthcare | July 23, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral...
AIDS 2024, the 25th International AIDS Conference; July 22-26, 2024; Munich, Germany |
![](../Main_/PICTURES/grey_square2.gif) |
Ongoing Stigma Remains a Major Obstacle in the Fight Against HIV
Manager Healthcare | July 23, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Germany calls for intensified global efforts to combat AIDS epidemic
Anadolu Agency | July 23, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
An Isolated Viral Load Test May Generate False Positive Results for People Using Long-Acting PrEP
HIV.gov | July 23, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Unfinished business: only urgent and accelerated delivery of HIV services will keep the promise of ending AIDS in children by 2030
UNICEF | July 22, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
New UNAIDS report shows AIDS pandemic can be ended by 2030, but only if leaders boost resources and protect human rights now
UNAIDS | July 22, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
WHO releases technical brief on reducing HIV-related stigma and discrimination in healthcare settings
WHO | July 22, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Breakthrough in HIV cure: Seventh person worldwide appears cured
The Jerusalem Post | July 21, 2024
|
![](../Main_/PICTURES/grey_square2.gif) |
Research to watch out for at AIDS 2024
i-base | July 18, 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
Business Wire | July 16, 2024 |
![](../Main_/PICTURES/grey_square2.gif) |
ViiV Healthcare To Announce Data From Largest Head-To-Head Randomised Clinical Trial For 2-Drug Regimen Dovato Against 3-Drug...
ViiV Healthcare | July 15, 2024
|
|
|
|
|
|
|
|
![](AIDS2025.png) |
14–17 July 2025
The 13th IAS Conference on HIV Science
IAS 2025, the 13th IAS Conference on HIV Science, will take place in Kigali, Rwanda, from 14 to 17 July 2025. Pre-meetings will be held on 13 July. An estimated 6,000 participants from around the world will attend IAS 2025.
The IAS Conference on HIV Science is the world’s most influential meeting on HIV research and its applications. This biennial conference presents the critical advances in basic, clinical and operational HIV research that move science into policy and practice. Through its open and inclusive programme, the meeting sets the gold standard of HIV science, featuring highly diverse and cutting-edge research.
|
|
|
|
|
|